Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 May 23;26(22):2788-95.
doi: 10.1016/j.vaccine.2008.02.071. Epub 2008 Mar 31.

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

Walter Jaoko  1 , Frederick N Nakwagala, Omu Anzala, Gloria Omosa Manyonyi, Josephine Birungi, Annet Nanvubya, Farah Bashir, Kirana Bhatt, Hilda Ogutu, Sabina Wakasiaka, Lucy Matu, Wambui Waruingi, Jane Odada, Micah Oyaro, Jackton Indangasi, Jeckonia Ndinya-Achola, Carol Konde, Emmanuel Mugisha, Patricia Fast, Claudia Schmidt, Jill Gilmour, Tony Tarragona, Carol Smith, Burc Barin, Len Dally, Bruce Johnson, Andrew Muluubya, Leslie Nielsen, Peter Hayes, Mark Boaz, Peter Hughes, Tomás Hanke, Andrew McMichael, Job Bwayo, Pontiano Kaleebu
Affiliations
Clinical Trial

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

Walter Jaoko et al. Vaccine. .

Abstract

The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources